SCHEMBL17572930

SCHEMBL17572930

COC(=O)N1CCC(Oc2cc(C(=O)O)ncn2)CC1

nearest known ligand 0.48

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
GPR119 Q8TDV5 15/20 0.48
S1PR1 P21453 3/20 0.45
KMO O15229 2/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17559376 0.99 GPR119 (0.47) GPR119S1PR1KMO
SCHEMBL17559481 0.90 GPR119 (0.48) GPR119S1PR1
Lithium Ion SCHEMBL17559375 0.88 GPR119 (0.47) GPR119S1PR1
SCHEMBL17559337 0.85 GPR119 (0.49) GPR119S1PR1
SCHEMBL17559414 0.79 PRMT5 (0.46) GPR119
SCHEMBL2775980 0.78 S1PR1 (0.61) S1PR1KMO
SCHEMBL17572982 0.76 NOS3 (0.51) GPR119
SCHEMBL17559447 0.75 HRH3 (0.50) GPR119
SCHEMBL19473336 0.73 TLR8 (0.46) GPR119
SCHEMBL289843 0.72 EGFR (0.41) GPR119S1PR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY. LTD. (AU) 2017-10-19 US disclosed
WO-2016034673-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS CTXT PTY LTD (AU) 2016-03-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170298075-A1 TETRAHYDROISOQUINOLINE DERIVED PRMT5-INHIBITORS PRMT5, PRMT1, PRMT3 GPR119 3993/4885S1PR1 3847/4885KMO 1153/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.